- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04219371
Reference Range Study for the Quantra QStat System
July 24, 2020 updated by: HemoSonics LLC
The objective is to determine the reference range intervals for the parameters reported by the Quantra System with the QStat Cartridge.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, prospective, observational study of a healthy adult population with normal coagulation function to determine the reference range intervals for the parameters reported by the Quantra System with the QStat Cartridge.
The threshold for the Clot Stability to Lysis (CSL) parameter will be determined from the CSL reference range.
Study Type
Observational
Enrollment (Actual)
140
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Sandy Springs, Georgia, United States, 30328
- WR-Mount Vernon Clinical Research, LLC
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- M3 Wake Research
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37421
- WR-Clinsearch, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adult volunteers with normal coagulation function, approximately equal numbers of males and females across three age group categories (18-30, 31-50 and >50 years).
The racial and ethnic profiles will be representative of the populations at each site.
Description
Inclusion Criteria:
- Subject is 18 years or older
- Subject is willing to participate and has signed a consent form
- Subject's laboratory coagulation test results at screening are within each test's normal reference range.
Exclusion Criteria:
- Subject is younger than 18 years
- Subject has a history of a coagulation disorder
- Subject is pregnant or lactating
- Subject is currently taking medications known to alter coagulation
- Subject has one or more laboratory coagulation test results outside of the normal reference range at screening
- Subject had a blood transfusion or surgery within the last month
- Drug abuse
- Excessive alcohol consumption
- Subject is unable to provide written informed consent
- Subject is incarcerated at the time of the study
- Subject previously participated in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Healthy volunteers
Blood samples from healthy volunteers analyzed on the Quantra System.
|
Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reference range intervals for measurement of Clot Time (CT) parameter
Time Frame: Baseline, determined from a single blood draw
|
Reference range intervals determined in this study will serve as the reference range for CT on the QStat Cartridge when it is commercially available.
|
Baseline, determined from a single blood draw
|
|
Reference range intervals for measurement of Clot Stiffness (CS) parameter
Time Frame: Baseline, determined from a single blood draw
|
Reference range intervals determined in this study will serve as the reference range for CS on the QStat Cartridge when it is commercially available.
|
Baseline, determined from a single blood draw
|
|
Reference range intervals for measurement of Fibrinogen Contribution to Clot Stiffness (FCS) parameter
Time Frame: Baseline, determined from a single blood draw
|
Reference range intervals determined in this study will serve as the reference range for FCS on the QStat Cartridge when it is commercially available.
|
Baseline, determined from a single blood draw
|
|
Reference range intervals for measurement of Platelet Contribution to Clot Stiffness (PCS) parameter
Time Frame: Baseline, determined from a single blood draw
|
Reference range intervals determined in this study will serve as the reference range for PCS on the QStat Cartridge when it is commercially available.
|
Baseline, determined from a single blood draw
|
|
Reference range intervals for measurement of Clot Stability to Lysis (CSL) parameter
Time Frame: Baseline, determined from a single blood draw
|
Reference range intervals determined in this study will serve as the reference range for CSL on the QStat Cartridge when it is commercially available.
|
Baseline, determined from a single blood draw
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 7, 2020
Primary Completion (Actual)
April 17, 2020
Study Completion (Actual)
June 30, 2020
Study Registration Dates
First Submitted
January 2, 2020
First Submitted That Met QC Criteria
January 3, 2020
First Posted (Actual)
January 7, 2020
Study Record Updates
Last Update Posted (Actual)
July 28, 2020
Last Update Submitted That Met QC Criteria
July 24, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HEMCS-031
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coagulation Disorder
-
Meir Medical CenterUnknownCoagulation Disorder | Blood Coagulation Disorder | Blood Clot | Anticoagulants; Increased | Anticoagulant Overdosage
-
University Hospital, CaenUnknownBlood Coagulation Disorders | Blood Coagulation Disorder With Prolonged Bleeding Time | Blood Coagulation Disorder With Prolonged Coagulation TimeFrance
-
VarmX B.V.Active, not recruitingCoagulation DisorderNetherlands
-
Groupe Hospitalier Paris Saint JosephCompletedCoagulation DisorderFrance
-
Cairo UniversityRecruitingCoagulation DisorderEgypt
-
Stony Brook UniversityCompletedCoagulation DisorderUnited States
-
Masaryk Hospital Krajská zdravotní a.s.CompletedCoagulation Disorder | Multiple Trauma | Coagulation Defect; Acquired | Coagulation Factor DeficiencyCzechia
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
VarmX B.V.Completed
Clinical Trials on Quantra System
-
HemoSonics LLCCompletedCoagulationUnited States
-
HemoSonics LLCCompletedBlood Loss, SurgicalUnited States
-
HemoSonics LLCNot yet recruiting
-
HemoSonics LLCNot yet recruitingPediatric | CoagulationUnited States, Switzerland
-
HemoSonics LLCCompletedTrauma | Blood Loss MassiveUnited States
-
HemoSonics LLCCompletedBlood Loss, SurgicalUnited States
-
HemoSonics LLCCompleted
-
HemoSonics LLCUniversity of California, IrvineCompletedThrombosis | Blood Loss | Extracorporeal Circulation; ComplicationsUnited States
-
HemoSonics LLCCompleted